Brief: Biocryst Pharmaceuticals Updates Commercialization Agreement With Torii Pharmaceutical In Japan

BioCryst Pharmaceuticals

30/11/2023 14:20

Nov 30 (Reuters) - BioCryst Pharmaceuticals Inc
 BCRX.O :
    * BIOCRYST PHARMACEUTICALS - UPDATED COMMERCIALIZATION
AGREEMENT
WITH TORII PHARMACEUTICAL CO., LTD. FOR ORLADEYO(REG)
(BEROTRALSTAT) IN JAPAN
    * BIOCRYST PHARMACEUTICALS INC - BIOCRYST JAPAN K.K. WILL
NOW BE
RESPONSIBLE FOR ALL COMMERCIAL PROMOTION ACTIVITIES TO SUPPORT
ORLADEYO SALES IN JAPAN
    * BIOCRYST PHARMACEUTICALS INC - TORII WILL BE RESPONSIBLE
FOR
HEREDITARY ANGIOEDEMA (HAE) DISEASE AWARENESS ACTIVITIES IN
JAPAN
    * BIOCRYST PHARMACEUTICALS - UNDER AMENDED ROYALTY STRUCTURE
CO TO
RECEIVE 20% ROYALTY ON ANNUAL JAPANESE SALES BELOW PRESPECIFIED
THRESHOLD
    * BIOCRYST PHARMACEUTICALS - UNDER AMENDED ROYALTY STRUCTURE
CO TO
RECEIVE 80% ROYALTY ON ANNUAL JAPANESE SALES ABOVE PRESPECIFIED
THRESHOLD

Source text for Eikon:  ID: 
Further company coverage:  BCRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))